SPONSOR
Fred Hutchinson Cancer Center
Total Trials
4
Recruiting
4
Phases
Phase 2, Phase 1, Phase 2, Phase 1
Conditions studied: Acute Leukemia of Ambiguous LineageAcute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic SyndromeAcute Lymphoblastic Leukemia in RemissionAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia in RemissionMyelodysplastic Syndrome With Excess BlastsRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid Leukemia
Fred Hutchinson Cancer Center is a clinical research sponsor with 4 registered studies on ClinicalTrials.gov, of which 4 are actively recruiting participants. Research covers conditions including Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome.
The trial portfolio spans Phase 2, Phase 1, Phase 2, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Fred Hutchinson Cancer Center
How many clinical trials has Fred Hutchinson Cancer Center sponsored?
ClinicalMetric currently tracks 4 clinical trials sponsored by Fred Hutchinson Cancer Center, of which 4 are actively recruiting participants. These trials cover conditions including Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Fred Hutchinson Cancer Center research focus on?
Fred Hutchinson Cancer Center clinical trials span Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia in Remission, and additional conditions. The research pipeline includes Phase 2, Phase 1, Phase 2, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Fred Hutchinson Cancer Center clinical trial?
To participate in a Fred Hutchinson Cancer Center trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Fred Hutchinson Cancer Center trials with current recruitment status updated daily.
Clinical Trials by Fred Hutchinson Cancer Center
NCT07046078 Phase 2
Recruiting
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Acute Leukemia of Ambiguous Lineage
NCT03670966 Phase 1, Phase 2
Recruiting
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Acute Lymphoblastic Leukemia in Remission
NCT06922188
Recruiting
Development of Measures to Screen for Financial Hardship in Alzheimer's Disease and Dementia
Financial Hardship
NCT06609928 Phase 1
Recruiting
FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
Recurrent Childhood Acute Myeloid Leukemia
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology